Peptide Initiative

Peptide profile · Healing & Recovery

KPV (Alpha-MSH Fragment)

Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation

Strong human trialsResearch compound
Short peptide half-life; improved by nanoparticle and hydrogel formulationsHalf-life
Oral uptake via PepT1 transporter; enhanced by nanoparticle formulationsBioavailability
342.43Molecular weight, Da

Molecular formula

C16H30N4O4

CAS number
67727-97-3
PubChem
125672
Developed · 2002
Academic research groups, University of Kiel, University of Iowa and Chinese Academy of Sciences, among others

Amino acid sequence

Lys-Pro-Val (alpha-MSH residues 11-13)

Anti-InflammatoryPotent NF-κB and MAP kinase pathway inhibitor that significantly reduces TNF-α, IL-1β, and IL-6 at nanomolar concentrations in preclinical IBD models

9.2

Gut HealthSelectively targets inflamed intestinal epithelium via PepT1 transporter with demonstrated efficacy in DSS and TNBS colitis models

9.0

Healing & RecoveryPreserves intestinal epithelial barrier integrity, reduces inflammatory infiltration, and promotes tissue recovery in damaged mucosal tissue

8.0

Ratings out of 10.

200 – 500mcg

Every documented dose level

PhaseDoseFrequencyRoute
Weeks 4-6200 mcgOnce dailySubcutaneous
Weeks 4-6300-500 mcgOnce dailySubcutaneous
Weeks 4-61000-1500 mcgOnce dailyOral
Weeks 4-80.01-0.1% cream or serumTwice dailyTopical
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for inflammatory bowel disease research & gut anti-inflammatory therapy development

Best for

  • Inflammatory bowel disease research

    KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Gut anti-inflammatory therapy development

    KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Skin inflammation and wound healing

    KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Cytokine-mediated inflammation studies

    KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for healing & recovery supportConsult your healthcare provider for alternatives to KPV (Alpha-MSH Fragment) based on your specific needs and medical history
Alternative healing peptidesBPC-157TB-500 (Thymosin Beta-4)GHK-Cu
Non-peptide recovery optionsPlatelet-Rich Plasma (PRP)Collagen supplementsPhysical therapy

Do not use if

  • Not approved for human clinical use
  • Unknown interactions with immunosuppressive medications
  • Insufficient safety data for pregnancy and lactation
  • Potential melanocortin receptor effects in susceptible individuals

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about KPV (Alpha-MSH Fragment) use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare KPV (Alpha-MSH Fragment) with similar peptides to find the best fit for your goals.

Route

KPV (Alpha-MSH Fragment) is administered Oral—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

The KPV (Alpha-MSH Fragment) injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

5 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data.

The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation.

Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.

KPV safety data come from in vitro mechanistic studies, rodent models, and limited human topical application research. Published research in Journal of Neuroimmunology demonstrates selective anti-inflammatory activity without systemic toxicity signals in animal models.

Human safety data are restricted primarily to pilot studies and unpublished investigations, placing KPV in the research compound category with incomplete clinical characterization. Animal studies show no organ toxicity or genotoxicity at relevant doses.


Common side effects · experienced by some users

Injection Site Reaction

Potential mild redness, swelling, or discomfort at subcutaneous injection site as expected with peptide administration

Management
Rotate injection sites; apply ice if needed; standard subcutaneous injection technique

Mild GI Effects

Theoretical mild gastrointestinal symptoms with oral administration as peptide interacts with intestinal epithelium

Management
Take with food if GI discomfort occurs; start with lower doses and titrate upward

Transient Skin Effects

With topical application, potential mild irritation or redness at application site during initial use

Management
Patch test before widespread application; reduce concentration if irritation occurs

Mild Immune Modulation

Anti-inflammatory effects may transiently alter local immune responses at sites of inflammation

Management
Monitor for signs of infection; effects are expected to be reversible upon discontinuation

Peptide Stability Concerns

As a small peptide, KPV is susceptible to proteolytic degradation which may affect bioavailability rather than cause side effects

Management
Use nanoparticle or hydrogel formulations for improved stability; subcutaneous route may offer better bioavailability than oral

Serious side effects

Immune Tolerance Development

Chronic immune suppression through KPV could theoretically lead to immune tolerance or reduced responsiveness to infectious agents or vaccine challenges, though clinical evidence is limited.

Management
Monitor immune function parameters; avoid prolonged continuous use without breaks; maintain vaccination schedules; counsel on increased infection risk if combined with other immunosuppressants; ensure adequate nutrition and sleep.

Less commonTheoretical Immunosuppression

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with KPV (Alpha-MSH Fragment)
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

KPV (Alpha-MSH Fragment) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeBPC-157 — Complementary gut-healing peptide that promotes mucosal repair while KPV addresses underlying inflammation
  • SafeThymosin Alpha-1 — Immune-modulating peptide that can complement KPV anti-inflammatory effects for balanced immune regulation
  • SafeL-Glutamine — Amino acid that supports intestinal barrier function and mucosal integrity alongside KPV anti-inflammatory action

With medications

  • CautionHigh-Dose Immunosuppressants — Additive immune suppression may increase infection risk through overlapping anti-inflammatory mechanisms
  • CautionMelanotan Peptides — Potential overlapping melanocortin receptor activation could produce unpredictable combined effects
  • CautionSystemic Corticosteroids — Redundant anti-inflammatory pathways may confound therapeutic outcomes or cause excessive immune suppression

With supplements

  • SafeMultivitamins — Generally safe to take alongside KPV (Alpha-MSH Fragment). Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs initial response (1-2 weeks)

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

KPV is a three-amino-acid peptide that suppresses inflammatory responses in your immune system.

It works by reducing pro-inflammatory signals and modulating immune cells, making it useful for treating inflammatory skin conditions. KPV calms overactive immune responses without suppressing overall immunity, offering anti-inflammatory benefits similar to steroids but through a safer mechanism.

The deeper mechanism

KPV (lysine-proline-valine) is a tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH) that functions as a potent anti-inflammatory agent through multiple mechanisms.

KPV inhibits NF-κB-dependent pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) in activated macrophages and epithelial cells, reduces mast cell degranulation and histamine release, and activates anti-inflammatory IL-10 production.

Unlike broad immunosuppressants, KPV selectively dampens Th1 and Th17 responses while preserving Th2 and regulatory T cell populations, achieving immunomodulation rather than immunosuppression.

KPV acts through melanocortin receptors (particularly MC1R on immune cells) and TLR4-dependent signaling to reduce NF-κB nuclear translocation. This mechanism makes KPV effective for inflammatory dermatitis, bacterial lip infections (impetigo), and inflammatory intestinal conditions.


What to expect

  1. Initial Response (1-2 Weeks)

    What you might notice

    • Anti-inflammatory signaling initiated;
    • reduction in acute inflammatory markers;
    • early improvement in intestinal symptoms in research models

    What's normal

    • Full integration of KPV (Alpha-MSH Fragment) into physiological systems is established
    • Long-term KPV (Alpha-MSH Fragment) response remains personalized to your physiology
    • KPV (Alpha-MSH Fragment) tolerance is well-maintained with consistent dosing

    What's next

    • Maintain your established KPV (Alpha-MSH Fragment) protocol for sustained benefits
    • Continue periodic monitoring to confirm KPV (Alpha-MSH Fragment) efficacy
    • Review comprehensive KPV (Alpha-MSH Fragment) response with your provider
  2. Active Anti-Inflammatory Phase (2-6 Weeks)

    What you might notice

    • Significant cytokine reduction;
    • improved intestinal barrier function;
    • measurable reduction in myeloperoxidase activity and inflammatory infiltrates

    What's normal

    • KPV (Alpha-MSH Fragment) has achieved stable, long-term homeostatic integration
    • Sustained efficacy of KPV (Alpha-MSH Fragment) remains consistent
    • Chronic KPV (Alpha-MSH Fragment) effects remain stable and predictable

    What's next

    • Maintain your established KPV (Alpha-MSH Fragment) protocol for sustained benefits
    • Continue periodic monitoring to confirm KPV (Alpha-MSH Fragment) efficacy
    • Review comprehensive KPV (Alpha-MSH Fragment) response with your provider
  3. Sustained Benefit (6-12 Weeks)

    What you might notice

    • Maximum anti-inflammatory and barrier-protective effects;
    • prevention of disease progression in chronic models;
    • potential for mucosal healing

    What's normal

    • Full therapeutic effects of KPV (Alpha-MSH Fragment) are well-characterized at this point
    • Maintenance of KPV (Alpha-MSH Fragment)'s therapeutic effects is typical
    • Tolerance patterns with KPV (Alpha-MSH Fragment) are generally stable over months

    What's next

    • Comprehensive assessment of KPV (Alpha-MSH Fragment) efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to KPV (Alpha-MSH Fragment) over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

How is KPV related to alpha-MSH?

KPV consists of the last three amino acids (Lys-Pro-Val, positions 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). While it does not contain the melanocortin receptor pharmacophore of the parent hormone, it retains potent anti-inflammatory properties through NF-κB and MAP kinase pathway inhibition, making it the minimal anti-inflammatory fragment of alpha-MSH.

Why is KPV particularly promising for inflammatory bowel disease?

KPV has a unique advantage for IBD because it is selectively transported into intestinal epithelial cells and immune cells by the PepT1 transporter, which is significantly upregulated during intestinal inflammation. This provides targeted delivery to inflamed tissue with minimal systemic effects. Studies show approximately 50% reduction in colonic myeloperoxidase activity in colitis models.

Can KPV be taken orally?

Yes, KPV has demonstrated oral efficacy in preclinical models when added to drinking water at concentrations of approximately 100 micromolar. However, as a small peptide, it is susceptible to proteolytic degradation. Advanced delivery systems including hyaluronic acid-functionalized nanoparticles and hydrogel formulations have been developed to improve oral bioavailability.

Is KPV FDA approved?

No, KPV is not FDA approved for any indication. It remains a research compound with strong preclinical evidence but no published Phase 1-2 human clinical trials. It is available commercially as a research peptide and is used in investigational settings.

How does KPV compare to existing IBD medications?

In preclinical models, KPV offers potential advantages over current IBD treatments. Unlike systemic immunosuppressants, it targets inflammation locally through PepT1-mediated uptake. Unlike biologics targeting single cytokines, KPV inhibits the upstream NF-κB pathway affecting multiple inflammatory mediators. It has shown efficacy without observed adverse effects, though direct human comparisons are not yet available.

What delivery methods have been studied for KPV?

Three main delivery approaches have been investigated: direct oral administration in solution, hyaluronic acid-functionalized nanoparticles (which efficiently target inflamed gut mucosa), and cysteamine-grafted gamma-polyglutamic acid hydrogels (which stabilize the peptide and provide controlled release). Nanoparticle formulations have shown the most promise for enhancing oral bioavailability and targeting efficacy.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for KPV (Alpha-MSH Fragment), on one page.

KPV (Alpha-MSH Fragment) dosing protocol

Medical disclaimer

KPV (Alpha-MSH Fragment) is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026